We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

LGC Clinical Diagnostics

LGC Clinical Diagnostics is a leading provider of Quality Measurement Tools, biological materials, and reagents for t... read more Featured Products: More products

Download Mobile App





LGC Clinical Diagnostics Presents Seraseq and ACCURUN Range of Diagnostic Solutions

By LabMedica International staff writers
Posted on 12 Nov 2024

LGC Clinical Diagnostics (Middlesex, UK) is presenting its latest diagnostic solutions at this year’s MEDICA, including Seraseq and ACCURUN, which align with the increasing demand for personalized medicine and enhance clinical research capabilities, along with other best-in-class products across the company’s portfolio. More...

At MEDICA 2024, LGC is providing full access to its product brands including Technopath Clinical Diagnostics (IVD raw materials, independent quality controls, QC software solutions), SeraCare (quality controls, reference materials, biological materials, research), Biochemical Diagnostics (drugs of abuse testing), KOVA International (urinalysis controls), Maine Standards (linearity and calibration verification, calibrators, OEM PT/EQA samples), and The Native Antigen Company (viral and bacterial antigens & antibodies, reagent components).

LGC is highlighting SeraCare’s comprehensive suite of patient-like reference materials that accelerates development, streamlines validation, and ensures confidence in the results of today’s demanding clinical genomics assays. These platform-agnostic, ground-truth reference materials can be used through all development phases to verify actionable and challenging variants as well as complex genomic signatures in patient samples. These ready-to-use reference materials cover clinically relevant variants and all variant types - SNVs, INDELS, CNVs, and RNA fusions. Highly multiplexed, they provide significantly more data per NGS run, saving sequencing costs. They are also available in multiple formats to suit different workflow needs - purified DNA & RNA, ctDNA, encapsulated ctDNA in plasma, and FFPE.

LGC is also presenting SeraCare’s ACCURUN molecular controls and reference materials which are whole-cell or whole-organism external controls that help monitor all aspects of molecular testing methods and provide additional confidence in laboratory test results. A well-designed QC program can help labs avoid costly false-negative or false-positive results. ACCURUN molecular controls effectively detect low-positives closer to assay-specific cutoffs, enabling better detection of assay variability. The powerful ACCURUN controls and reference materials help to ensure complete control over assay performance monitoring.

Related Links:
LGC


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Enterovirus Test
Quanty Enterovirus System
New
Biochemistry Analyzer
Chemi+ 8100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.